Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating the efficacy and safety of QMF149 a combination of indacaterol acetate and mometasone furoate compared to budesonide in children aged 6 to less than 12 years who have asthma. This Phase 3, double-blind, randomized, active-controlled crossover study aims to determine whether QMF149 is superior in improving lung function measured by FEV1 in these children, who have at least 50% of the predicted normal value of FEV1. Participants undergo two treatment periods, each lasting 12 weeks, receiving either QMF149 7540 mcg once daily via Breezhaler or budesonide 200 mcg once daily via Breezhaler in a crossover design. The study includes a screening period of up to 3 weeks, a 3-week run-in period with fluticasone propionate 50 mcg twice daily, a 3-week washout period with the same medication, and a 4-week safety follow-up during which participants return to standard care. The total study duration is up to 37 weeks. Throughout the study, participants will attend visits at defined intervals, including screening, run-in, treatment, washout, and follow-up periods. Researchers will assess lung function changes FEV1, asthma control questionnaire scores, peak expiratory flow rates, rescue medication use, and monitor adverse events. Safety information and survival status will be collected after the follow-up period to ensure thorough evaluation of both treatments.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are studying healthcare workers who have either received a COVID-19 vaccine or had a confirmed SARS-CoV-2 infection. This observational study involves multiple centers across eight countries and aims to analyze how different virus variants affect immunity from vaccination and natural infection. The focus is on understanding how virus variants may evade immune protection from vaccines or past infections by examining both antibody and cellular immunity. Participants include adult healthcare workers aged 18 and older who have known vaccination or infection history. The study follows each participant from their first immune event, either infection or vaccination, with follow-up planned for up to 24 months. Blood and serum samples are collected every four months and sent to central laboratories where advanced statistical and artificial intelligence methods analyze immune responses and viral sequences to assess protection and immune escape. Participants will provide retrospective and prospective data and biological samples over one to two years, depending on immune persistence. Researchers measure neutralizing antibodies, cellular immunity, and viral variants to understand immunity duration and effectiveness against different SARS-CoV-2 variants. The study tracks the number of healthcare workers involved through an average of three years and collects data to help define cross-immunity among variants and the impact of vaccine and natural infection combinations.
Actively Recruiting
Researchers are evaluating the use of local thermotherapy as a treatment to help control mild-to-moderate COVID-19, caused by the SARS-CoV-2 virus. This virus is a positive-sense single-stranded RNA virus responsible for a global pandemic with varying fatality rates. Raising the temperature on affected areas may inhibit viral replication by producing small interfering RNAs that block viral transcription. Thermotherapy has been previously used to target RNA viruses, cancer cells, and parasitic infections, which supports its potential use against COVID-19 to reduce viral load and aid the immune response. The study compares two groups one receiving usual hospital care plus an electric heat pad applied to the chest for 90 minutes twice daily over 5 days, and the other receiving usual hospital care alone. The heat pad raises the skin temperature to 40-42 0C, a range expected to facilitate virus elimination without causing discomfort. The electric cushion is a commercially available device widely used for muscle pain and arthritis treatment. Participants will undergo evaluations over 28 days to monitor disease progression and other health outcomes such as mortality, time to severe or critical COVID-19, hospitalization duration, oxygen requirement, and adverse events. Clinical status will be assessed using scales like the National Early Warning Score 2 NEWS-2, and safety and tolerance of the thermotherapy will be tracked. The trial is randomized and open-label, with follow-up visits occurring at multiple time points during and after the treatment period.
Actively Recruiting
Researchers are investigating the long-term effects of COVID-19 by studying patients who have recovered from the acute phase of the disease to understand the prevalence and possible predictors of post COVID-19 condition. This condition involves symptoms that persist or newly appear at least three months after the initial infection, lasting for two or more months without another explanation. The study aims to identify factors such as age, gender, disease severity, and viral variants that may influence these ongoing symptoms and related organ damage. The study includes patients who have recovered from mild to severe COVID-19, with data collected retrospectively from post COVID-19 outpatient clinics and prospectively through ongoing follow-up visits. Patients undergo routine blood tests and evaluations by infectious disease specialists and other relevant medical professionals such as pulmonologists, cardiologists, neurologists, and psychologists, depending on individual clinical needs. Participants will be monitored over an average of three years to assess the incidence and persistence of post COVID-19 condition, identify risk factors, and evaluate long-term damage to organs including lungs, heart, and nervous systems. The study will also examine the role of different viral variants and immune responses. Data collection involves clinical visits, laboratory tests, and specialist assessments to provide a comprehensive understanding of post COVID-19 outcomes.